Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SoftOx Solutions AS ( (DE:6FV) ) has provided an announcement.
SoftOx Solutions AS’s subsidiary, SoftOx Defense Solutions AS, has submitted a Phase 1 Clinical Trial Application to the Irish Health Products Regulatory Authority. This trial, part of the European Defense Fund program, aims to assess the safety and tolerability of the SoftOx Inhalation Solution as a medical countermeasure against biological warfare threats. The successful progress of this trial could enhance SoftOx’s strategic position in developing dual-use technologies, appealing to global pharmaceutical partners.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo, developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The company collaborates with leading Nordic research institutes for its technology development.
YTD Price Performance: 421.43%
Average Trading Volume: 16,897,742
Current Market Cap: NOK172M
Learn more about 6FV stock on TipRanks’ Stock Analysis page.